CA - Appili to get US patent for antibiotic ATI-1501

• Appili Therapeutics ( OTCQB:APLIF ) said that it will get a patent from the U.S. Patent and Trademark Office (USPTO) for ATI-1501, a liquid oral reformulation of the antibiotic metronidazole.
• Metronidazole is used to treat parasitic and anaerobic bacterial infections. The tablet form of the drug is the only approved oral form on the U.S. market currently, the company added.
• "We are pleased with this notice of allowance for a new patent that will further strengthen ATI-1501’s potential as a more convenient antibiotic treatment option," said Appili President and CEO Don Cilla.
• Appili and its partner Saptalis Pharmaceuticals expect ATI-1501 to be approved by the FDA by the end of 2023.

For further details see: